Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Advertise in Pharma in Focus

Advertising in Pharma in Focus delivers you:

  • Unique access to a $17 billion industry
  • High visibility with over 11,500 readers every working day
  • Great reaction with click through rates of up to 6.5%
  • Unparalled contact via unique beyond-the-click services

For more information, ring 02 9938 4381

Pipeline Monitor
New RA drug in view
A new rheumatoid arthritis drug from Sanofi and more good news for MSD on blockbuster Keytruda were highlights among pipeline decisions this week.
Perspective
MSD v PBAC: it's all about the data
It might have been short but MSD's statement on the revised draft report of the post-market review of ezetimibe spoke volumes on how treatment of PBS data can skew conclusions to potentially alarming effect.
Approvals Action
New hope for metabolic disease
Alexion's orphan therapy Kanuma has been approved by the TGA for metabolic disease lysomal acid lipase deficiency.